Grace Therapeutics is an innovative specialty pharmaceutical company with a focus on rare and orphan disease. Grace's strategy is to develop novel delivery technologies that dramatically improve the clinical outcomes of drugs previously approved for use in humans. Our selective pipeline screening model supports the development of differentiated products with a unique evidence-based and outcomes-driven value proposition . Our pipeline consists of three distinct assets all in late stage clinical development for the treatment of Postherpetic Neuralgia, Subarachnoid Hemorrhage, and Ataxia Telangiectasia. We intend to pursue multiple commercialization options for these products including their proprietary platform technologies for maximum value creation. Our team comprises accomplished drug delivery scientists and commercial executives with a proven track record of bench-to-bedside success.